Company: RCUS
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001193125-25-028669
Chunk: 8

Company: Arcus Biosciences, Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 8
---
                                
 difficult to trace and enforce, and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. |

| • |     | We expect to expand our business operations and, as a result, we may encounter difficulties in managing our 
 growth, which could disrupt our operations.                                                                 |

| • |     | We face substantial competition, which may result in others discovering, developing or commercializing products                                                                                               
 more quickly or marketing them more successfully than us. If their investigational products are shown to be safer or more effective than ours, then our commercial opportunity will be reduced or eliminated. |

| • |     | Our internal information technology systems, and those of our third-party CROs and other third parties upon which                                                                                                                                 
 we rely, are subject to failure, security breaches and other disruptions, which could result in a material disruption of our investigational products’ development programs, jeopardize sensitive information, prevent us from accessing critical 
 information or result in a loss of our assets, and potentially expose us to notification obligations, loss, liability or reputational damage and otherwise adversely affect our business.                                                         |

| • |     | Failure to comply with privacy and data protection laws, regulations or other obligations could lead to                                                                                        
 government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. |

| • |     | Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our                         
 business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. |

Corporate Information We were incorporated in Delaware on April 30, 2015. Our principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545, and our telephone number is (510) 694-6200.Our website address is www.arcusbio.com. The information on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. Arcus Biosciences and the Arcus Biosciences logo are the property of Arcus. Trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders.

S-5

The Offering

| Common stock offered by us | 13,636,364 shares |

| Common stock to be outstanding immediately after 
 this offering                                    | 105,137,